ARTICLE | Finance
NanoDimension backs sight-restoring therapy developer Arctos in series A
For its first life sciences company creation deal in Europe, NanoDimension launches ophthalmic play from third fund
December 13, 2019 8:33 PM UTC
Updated on Dec 13, 2019 at 8:54 PM UTC
Newly launched Arctos will use CHF8 million in series A money to conduct preclinical work on a vector-delivered technology it believes can restore eyesight in patients whose retinal cells have degenerated, rather than those whose blindness is caused by genetic disorders.
Basel-based Arctos Ltd. has the support of NanoDimension, which led the round with a CHF6 million ($6.1 million) investment, and Novartis Venture Fund, which provided the balance. NanoDimension has begun emphasizing company creation in Europe with its $335 million third fund, which closed in May...